A detailed history of Gibbs Wealth Management transactions in Astrazeneca PLC stock. As of the latest transaction made, Gibbs Wealth Management holds 14,444 shares of AZN stock, worth $1.29 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
14,444
Previous 14,591 1.01%
Holding current value
$1.29 Million
Previous $1.02 Billion 8.67%
% of portfolio
0.25%
Previous 0.2%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 30, 2025

SELL
$68.72 - $82.11 $10,101 - $12,070
-147 Reduced 1.01%
14,444 $1.11 Billion
Q2 2025

Aug 13, 2025

BUY
$64.87 - $75.0 $946,518 - $1.09 Million
14,591 New
14,591 $1.02 Billion
Q1 2025

Nov 04, 2025

BUY
$65.37 - $77.96 $59,486 - $70,943
910 Added 7.0%
13,903 $1.02 Billion
Q4 2024

Nov 04, 2025

BUY
$63.2 - $79.58 $165,268 - $208,101
2,615 Added 25.2%
12,993 $851 Million
Q3 2024

Nov 04, 2025

SELL
$76.67 - $87.62 $311,740 - $356,262
-4,066 Reduced 28.15%
10,378 $809 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $276B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Gibbs Wealth Management Portfolio

Follow Gibbs Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gibbs Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Gibbs Wealth Management with notifications on news.